Darolutamide

Evidence Level: L5

Predicted Indications: 3

Darolutamide

Pharmacist Assessment Report

Darolutamide: From Prostate Cancer to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Darolutamide is a non-steroidal androgen receptor antagonist, marketed in Australia as Nubeqa 300 mg tablets. The approved indication text was not available in the data compiled for this report. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolaemia, but there are 0 clinical trials and 0 publications supporting this prediction. It is a model-only prediction with no supporting evidence.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report (darolutamide is an androgen receptor antagonist used in prostate cancer)
Predicted New Indication	Homozygous familial hypercholesterolaemia
TxGNN Prediction Score	0.9911
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Darolutamide is known to be a non-steroidal androgen receptor antagonist.

The prediction is difficult to justify. Homozygous familial hypercholesterolaemia is caused by defects in the LDL receptor pathway (LDLR, APOB, PCSK9, LDLRAP1), which has no established link to androgen receptor blockade. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. There is no supporting clinical or literature evidence.

Other top-ranked predictions are similarly unsupported. HIV infectious disease is a viral condition, and this pattern may reflect similarities the model learned between related diseases rather than real therapeutic signals. The only candidate with any trial matches is multiple endocrine neoplasia (rank 2), but those trials relate to prostate cancer, not to this condition.

Clinical Trial Evidence

Currently no related clinical trials registered for homozygous familial hypercholesterolaemia.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 12684N	Nubeqa	Tablet 300 mg (oral)	Not available in the data compiled for this report

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted/endocrine therapy (androgen receptor antagonist), not a conventional cytotoxic
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the Product Information (PI) warnings and precautions
Handling Protection	Please refer to the Product Information (PI) warnings and precautions

Safety Considerations

Key warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Drug Interactions: The interaction screen returned 100 interacting drugs, of which 20 are listed in the data compiled for this report. Selected examples:

Major: dexamethasone, eluxadoline, rosuvastatin
Moderate: clarithromycin, empagliflozin, glyburide, repaglinide, simvastatin, sulfasalazine, cobicistat, deferasirox, eltrombopag
Minor: aprepitant, cimetidine, miconazole

The rosuvastatin (major) and simvastatin (moderate) interactions are particularly relevant, as statins are standard therapy in familial hypercholesterolaemia. Darolutamide is also known to have CYP3A4, P-gp and BCRP interaction potential, which would complicate combination use.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a TxGNN model (deep learning) score, which may reflect similarities the model learned between related diseases, not biological evidence. There is no plausible mechanistic link, no clinical trials and no literature, and a notable interaction with statins would complicate its use in this population.

To proceed, the following is needed:

Mechanistic evidence linking androgen receptor antagonism to LDL receptor pathway defects
Preclinical data in relevant models
Approved indication text and TGA Product Information (warnings and contraindications)
Statin and lipid-lowering drug interaction assessment
Consideration of other candidates only if supported by evidence. None of the other nine predictions currently show credible support.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.